These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34576115)

  • 21. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
    Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
    J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-derived CD4+CD25+ Tregs inhibit the maturation and antigen-presenting function of dendritic cells.
    Du Y; Chen X; Lin XQ; Wu W; Huang ZM
    Asian Pac J Cancer Prev; 2015; 16(7):2665-9. PubMed ID: 25854343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-related HSP70 released after cryo-thermal therapy targeted innate immune initiation in the antitumor immune response.
    Zhu J; Lou Y; Liu P; Xu LX
    Int J Hyperthermia; 2020; 37(1):843-853. PubMed ID: 32654540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis.
    Chopra M; Riedel SS; Biehl M; Krieger S; von Krosigk V; Bäuerlein CA; Brede C; Jordan Garrote AL; Kraus S; Schäfer V; Ritz M; Mattenheimer K; Degla A; Mottok A; Einsele H; Wajant H; Beilhack A
    Carcinogenesis; 2013 Jun; 34(6):1296-303. PubMed ID: 23385062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.
    Kitamura N; Murata S; Ueki T; Mekata E; Reilly RT; Jaffee EM; Tani T
    Int J Cancer; 2009 Aug; 125(3):630-8. PubMed ID: 19455675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway.
    Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D
    Front Immunol; 2018; 9():1274. PubMed ID: 29922294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.
    Pierini A; Strober W; Moffett C; Baker J; Nishikii H; Alvarez M; Pan Y; Schneidawind D; Meyer E; Negrin RS
    Blood; 2016 Aug; 128(6):866-71. PubMed ID: 27365424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of tumor necrosis factor-α induced protein 8 like-2 contributes to the immunosuppressive property of CD4(+)CD25(+) regulatory T cells in mice.
    Luan YY; Yao YM; Zhang L; Dong N; Zhang QH; Yu Y; Sheng ZY
    Mol Immunol; 2011 Oct; 49(1-2):219-26. PubMed ID: 21963221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
    Salomon BL; Leclerc M; Tosello J; Ronin E; Piaggio E; Cohen JL
    Front Immunol; 2018; 9():444. PubMed ID: 29593717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells.
    Chen X; Bäumel M; Männel DN; Howard OM; Oppenheim JJ
    J Immunol; 2007 Jul; 179(1):154-61. PubMed ID: 17579033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional plasticity of antigen-specific regulatory T cells in context of tumor.
    Addey C; White M; Dou L; Coe D; Dyson J; Chai JG
    J Immunol; 2011 Apr; 186(8):4557-64. PubMed ID: 21389255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.
    Knutson KL; Dang Y; Lu H; Lukas J; Almand B; Gad E; Azeke E; Disis ML
    J Immunol; 2006 Jul; 177(1):84-91. PubMed ID: 16785502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TNFR2-expressing CD4
    He J; Li R; Chen Y; Hu Y; Chen X
    Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells.
    Jung K; Kim JA; Kim YJ; Lee HW; Kim CH; Haam S; Kim YS
    Cancer Immunol Res; 2020 Jan; 8(1):46-56. PubMed ID: 31554638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-γ Drives T
    Overacre-Delgoffe AE; Chikina M; Dadey RE; Yano H; Brunazzi EA; Shayan G; Horne W; Moskovitz JM; Kolls JK; Sander C; Shuai Y; Normolle DP; Kirkwood JM; Ferris RL; Delgoffe GM; Bruno TC; Workman CJ; Vignali DAA
    Cell; 2017 Jun; 169(6):1130-1141.e11. PubMed ID: 28552348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis.
    Domvri K; Petanidis S; Zarogoulidis P; Anestakis D; Tsavlis D; Bai C; Huang H; Freitag L; Hohenforst-Schmidt W; Porpodis K; Katopodi T
    Clin Immunol; 2021 Jan; 222():108620. PubMed ID: 33176208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cells in vitro and in vivo.
    Cao Y; Feng YH; Gao LW; Li XY; Jin QX; Wang YY; Xu YY; Jin F; Lu SL; Wei MJ
    Int Immunopharmacol; 2019 May; 70():110-116. PubMed ID: 30798159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.